Romiplostim N01 Enhances Platelet Recovery in ASCT for Plasma Cell Disorders
Overview
Romiplostim N01 significantly accelerates platelet engraftment and recovery in patients undergoing autologous stem cell transplantation (ASCT) with non-cryopreserved peripheral blood stem cells (PBSCs). This approach also reduces hospitalization costs compared to traditional methods using cryopreserved PBSCs.
Background
Delayed platelet engraftment is a critical complication following ASCT for plasma-cell disorders, leading to increased risks of hemorrhage and prolonged hospital stays. Current supportive treatments are limited, highlighting the need for effective strategies to enhance thrombopoietic recovery. Romiplostim N01, a thrombopoietin receptor agonist, may offer a promising solution by stimulating megakaryocyte recovery.
Data Highlights
Parameter
Romiplostim N01
Control
P-value
Median Time to Platelet Engraftment (days)
11
13
0.008
Complete Platelet Recovery by Day +30
100%
66.7%
0.027
Total Hospitalization Cost (CNY)
77,609 ± 21,624
106,188 ± 14,910
<0.001
Key Findings
Platelet engraftment occurred significantly earlier in the Romiplostim N01 group (median 11 days) compared to controls (13 days).
Complete platelet recovery by day +30 was achieved in 100% of patients receiving Romiplostim N01 versus 66.7% in controls.
Hospitalization costs were significantly lower in the Romiplostim N01 cohort (77,609 CNY) compared to the control group (106,188 CNY).
Neutrophil recovery and transfusion requirements were comparable between both groups.
Safety profiles and survival outcomes were similar across both treatment groups.
Clinical Implications
The use of Romiplostim N01 in conjunction with non-cryopreserved PBSCs may provide a more effective and cost-efficient approach to managing thrombocytopenia in ASCT patients. Clinicians should consider this strategy to enhance patient outcomes and reduce healthcare costs associated with prolonged hospitalization.
Conclusion
Romiplostim N01 represents a viable option for accelerating platelet recovery in ASCT, offering both clinical benefits and reduced costs. Further studies are warranted to confirm these findings and optimize treatment protocols.
